Mesenchymal Cancer Biology Group


Sarcomas are a heterogeneous group of malignant tumours of mesenchymal origin that arise in various types of supporting and connective tissues. Sarcomas are rare, accounting for only 1% of all new malignancies, but 10-15% in young and adolescent patients. Although rare cancers together make up one of the largest patient groups with the by far most lost life-years, therapeutic research is difficult and neglected by industry due to low commercial potential. Thus, with some exceptions, the treatments have not improved significantly the last decades, and new strategies are required to improve outcome for these patients.


Ola Myklebost has changed his main affiliation to the University of Bergen from February 1st 2016, and our experienced postdoc Heidi Maria Namløs is managing the group while we are waiting for a new group leader to be employed.

From April 1st 2017, dr Jørgen Wesche will take helm